Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCT in Children With JMML
NCT00167219Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Nov 1999
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, cyclophosphamide, melphalan in juvenile myelomonocytic leukemia (JMML), sponsored by Masonic Cancer Center. Started Nov 1999; status: completed.
02
Drugs
busulfancyclophosphamidemelphalan
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT00167219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00167219.